JP2025517356A5 - - Google Patents
Info
- Publication number
- JP2025517356A5 JP2025517356A5 JP2024568250A JP2024568250A JP2025517356A5 JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5 JP 2024568250 A JP2024568250 A JP 2024568250A JP 2024568250 A JP2024568250 A JP 2024568250A JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- individual
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343506P | 2022-05-18 | 2022-05-18 | |
| US63/343,506 | 2022-05-18 | ||
| PCT/US2023/067146 WO2023225577A1 (en) | 2022-05-18 | 2023-05-17 | Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517356A JP2025517356A (ja) | 2025-06-05 |
| JP2025517356A5 true JP2025517356A5 (cg-RX-API-DMAC7.html) | 2026-05-18 |
Family
ID=88836107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568250A Pending JP2025517356A (ja) | 2022-05-18 | 2023-05-17 | 抗cd22抗体オリゴヌクレオチドコンジュゲートを使用したがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260115309A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4525930A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025517356A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250039518A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546345A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023225577A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4791443A1 (en) * | 2023-10-13 | 2026-08-19 | Tallac Therapeutics, Inc. | Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates |
| CN120324454A (zh) * | 2024-01-17 | 2025-07-18 | 安升(上海)医药科技有限公司 | 多肽-寡核苷酸复合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019360216A1 (en) * | 2018-10-17 | 2021-05-13 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotide conjugates and methods of use |
| IL295759A (en) * | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| US20230364255A1 (en) * | 2020-08-18 | 2023-11-16 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| TW202328185A (zh) * | 2021-08-25 | 2023-07-16 | 美商泰勒克療法公司 | SIRP-α抗體及結合物 |
-
2023
- 2023-05-17 KR KR1020247042026A patent/KR20250039518A/ko active Pending
- 2023-05-17 WO PCT/US2023/067146 patent/WO2023225577A1/en not_active Ceased
- 2023-05-17 CN CN202380051762.1A patent/CN119546345A/zh active Pending
- 2023-05-17 JP JP2024568250A patent/JP2025517356A/ja active Pending
- 2023-05-17 EP EP23808558.3A patent/EP4525930A1/en active Pending
-
2024
- 2024-11-14 US US18/948,373 patent/US20260115309A1/en active Pending